Kadmon Holdings Inc (NYSE:KDMN) Sees Large Decrease in Short Interest
Kadmon Holdings Inc (NYSE:KDMN) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 9,290,000 shares, a decline of 6.3% from the September 30th total of 9,910,000 shares. Based on an average daily volume of 659,300 shares, the short-interest ratio is presently 14.1 days. Approximately 8.1% of the shares of the stock are short sold.
In related news, major shareholder Perceptive Advisors Llc bought 1,470,588 shares of the stock in a transaction dated Monday, November 18th. The shares were acquired at an average cost of $3.40 per share, for a total transaction of $4,999,999.20. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.85% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California Public Employees Retirement System acquired a new position in Kadmon in the third quarter valued at approximately $56,000. Meeder Asset Management Inc. raised its position in Kadmon by 736.6% in the third quarter. Meeder Asset Management Inc. now owns 9,955 shares of the company’s stock valued at $25,000 after purchasing an additional 8,765 shares during the period. Macquarie Group Ltd. purchased a new stake in Kadmon in the second quarter valued at approximately $319,000. Susquehanna International Group LLP purchased a new stake in Kadmon in the second quarter valued at approximately $126,000. Finally, Boxer Capital LLC purchased a new stake in Kadmon in the second quarter valued at approximately $7,597,000. Hedge funds and other institutional investors own 76.80% of the company’s stock.
Several brokerages have recently weighed in on KDMN. ValuEngine cut Kadmon from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Cantor Fitzgerald upped their price objective on Kadmon from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Finally, Zacks Investment Research cut Kadmon from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $9.35.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.